Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

September 25, 2024

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions

August 13, 2024

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

August 12, 2024

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

July 25, 2024

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

July 15, 2024

Enveric Biosciences Announces Patent Granted for Drug Candidate

July 10, 2024

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

June 25, 2024

Enveric Biosciences to Participate in BIO International Convention 2024

May 30, 2024

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15, 2024

‹
1
2
3
4
…
14
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.